DMD is a rare hereditary disease that severely affects males, characterized by progressive muscle weakness and fibrosis. It may eventually lead to respiratory/heart failure, with a high mortality rate before the age of 30. As a new type of dissociative corticosteroid, AGAMREE® vamorolone has been approved in multiple key global markets (US, EU, UK, China, Canada, etc.), addressing core treatment pain points at the source:
1. Efficacy equivalent to first-line regimens: The pivotal VISION-DMD study confirmed that at a daily dose of 6mg/kg, its effect on improving motor function is consistent with traditional full-dose prednisone, with sustained efficacy for over 48 weeks. A 30-month long-term study showed that patients' standing ability remained superior to baseline.
2. Safety far exceeding traditional hormones: Compared with traditional hormones, the incidence of adverse reactions such as behavioral abnormalities, diabetes, skin problems, and infections is significantly lower. There is no risk of cataracts, and it does not affect bone metabolism or normal growth. Five-year long-term data further verify that it can maintain patients' growth and development and significantly reduce the rate of vertebral fractures.
As one of the world's first medical institutions to clinically apply AGAMREE® vamorolone, Beijing Jingdu Children's Hospital offers the world's lowest pricing, allowing international patients to access the same new drug treatment at an extremely low cost:
Region | Retail Price per Bottle (100ml:4g) (USD) | Monthly Average Drug Cost for 25kg Patients (USD) | Annual Average Drug Cost for 25kg Patients (USD) | Cost Ratio Compared to Jingdu Hospital |
Beijing Jingdu Children's Hospital | 1,683 | 1,894 | 23,042 | Benchmark (100%) |
United States | 9,844 | 11,075 | 134,744 | 17% of the US price |
United Kingdom | 6,013 | 6,765 | 82,303 | 28% of the UK price |
Germany | 5,173 | 5,820 | 70,807 | 32.5% of the German price |
Core advantage: The annual average drug cost is only 23,042 USD, saving over 110,000 USD per year compared to the US and nearly 60,000 USD per year compared to the UK. It significantly reduces the treatment burden on international patient families, making long-term standardized treatment no longer limited by costs.
Beijing Jingdu Children's Hospital has created a full-process medical service specifically for international DMD patients, making cross-border treatment more reassuring:
3. International-level medical team: A multidisciplinary team focused on DMD diagnosis and treatment has been established, with rich experience in rare disease treatment. It follows international clinical guidelines and provides standardized care synchronized with the world.
4. Drug accessibility guarantee: Sufficient drug inventory is available with no waiting time. Patients need to be hospitalized to obtain original genuine drugs, and long-term prescriptions are supported.
5. Convenient cross-border medical services: Multilingual consultation services (English, Japanese, Korean, etc.) are provided. It assists with medical visa processing, accommodation arrangements, transportation connections and other matters, simplifying the medical process.
Choose Beijing Jingdu Children's Hospital, choose a DMD treatment plan with "undiminished efficacy and significant cost reduction"!
No matter which country/region you are from, you can access top-tier globally recognized new DMD drug treatment and high-standard medical services here at the world's lowest cost. Beijing Jingdu Children's Hospital is a trusted choice for DMD patient families worldwide. We sincerely invite you to consult and seek treatment, moving towards health and hope together!
For inquiries about the international patient medical process, visa assistance or drug reservations, please directly contact the hospital's International Medical Department. We will provide you with one-on-one exclusive services.
EN
CN